Author: Grundler, P.V.
Paper Title Page
TUA03 The Use of PSI’s IP2 Beam Line Towards Exotic Radionuclide Development and its Application Towards Proof-Of-Principle Preclinical and Clinical Studies 132
  • N.P. van der Meulen, R. Eichler, P.V. Grundler, R. Hasler, W. Hirzel, S. Joray, D.C. Kiselev, R. Sobbia, A. Sommerhalder, Z. Talip, H. Zhang
    PSI, Villigen PSI, Switzerland
  • S. Braccini
    AEC, Bern, Switzerland
  Paul Scherrer Institute runs a High Intensity Proton Accelerator (HIPA) facility, where a maximum of 100 µA protons is gleaned from high intensity 72 MeV protons from Injector 2, a separated sector cyclotron, into the IP2 target station. These protons irradiate various targets towards the production of exotic radionuclides intended for medical purposes. Many radiometals in use today are for the diagnosis of disease, with the most popular means of detection being Positron Emission Tomography. These positron emitters are easily produced at low proton energies using medical cyclotrons, however, development at these facilities are lacking. The 72 MeV proton beam is degraded at IP2 using niobium to provide the desired energy to irradiate targets to produce the likes of 44Sc, 43Sc, 64Cu and 165Er*,**,***. Once developed, these proofs-of-principle are then put into practice at partner facilities. Target holders and degraders require development to optimize irradiation conditions and target cooling. Various options are explored, with pros and cons taken into consideration based on calculations and simulations.
* v/d Meulen et al., Nucl Med. Biol. (2015) 42: 745
** Domnanich et al., EJNMMI Radiopharm. Chemistry (2017) 2: 14
*** v/d Meulen et al., J Label Compd Radiopharm (2019) doi: 10.1002/jlcr.3730
slides icon Slides TUA03 [7.449 MB]  
DOI • reference for this paper ※  
About • paper received ※ 13 September 2019       paper accepted ※ 26 September 2019       issue date ※ 20 June 2020  
Export • reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)